The facility, in New York, US, will help develop dermal deliver formulations for 'problematic' compounds using its solubilizers and other products from its excipient portfolio – including liquid and semi-solid forms.
The chemical firm told us therapy areas will include wounds, acne, inflammatory rosacea, hyper pigmentary disorders and ophthalmic indications. It will also conduct clinical trials to test irritation and allergy reactions.
A spokesman told in-PharmaTechnologist.com a spokesman the decision to open the lab was based on the increasing importance of drug delivery via the skin as a compliance solution.
“Besides the necessity to improve solubility of active pharmaceutical ingredients (APIs) within the dermal formulation, the industry challenges are more focused on convenience, irritation and reduction of side effects.”
Of its client base, the company said it will collaborate with a “select group” of pharmaceutical innovators, generic manufacturers, and custom manufacturing, research and development organisations.
The move follows BASF’s 2010 takeover of Cognis pharma excipients.
Though the company has since divested the none-core units acquired as part of the deal, it retained a range of lipid-based emollients, surfactants, emulsifiers, gelling agents, waxes and solubilizers – which it says is now driving its dermatology business.
In a statement, the firm said: “The new pharmaceutical excipient portfolio now allows BASF to become a partner in human and animal dermatology, and topical, transdermal and liquid medicines.”
The spokesman also told us that BASF were keen to open the facility in New York because it is at the “forefront” of topical R&D.
“The new global laboratory for topical formulations is in close proximity to our key customers and our personal care laboratories at Tarrytown and Long Island. Both personal care laboratories are at the forefront of skincare research and formulation,” he said.